Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Marstacimab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Hympavzi contains the active substance marstacimab. Marstacimab is a monoclonal antibody, a type of protein designed to recognise and attach to a specific target in the body called tissue factor pathway inhibitor (TFPI). Hympavzi is a medicine used to prevent or reduce bleeding in patients 12 years of age and older, weighing at least 35 kg, with: • •
severe haemophilia A (congenital factor VIII deficiency, when the factor VIII blood level is less than 1%) who have not developed factor VIII inhibitors, or severe haemophilia B (congenital factor IX deficiency, when the factor IX blood level is less than 1%) who have not developed factor IX inhibitors.
Haemophilia A is an inherited bleeding disorder caused by a lack of factor VIII. Haemophilia B is an inherited bleeding disorder caused by lack of factor IX. Factor VIII and factor IX are proteins required for blood to clot and stop any bleeding. Some patients with haemophilia can develop factor VIII or factor IX inhibitors (antibodies in the blood that act against replacement factor VIII or factor IX medicines and prevent them from working properly). The active substance in Hympavzi, marstacimab, recognises and attaches to TFPI, a protein that prevents blood from clotting too much. By attaching to TFPI, marstacimab decreases how well it works, which promotes the formation of thrombin (a protein that plays a crucial role in blood clotting when there is an injury or damage to the body). This helps to increase clotting and stop bleeding in patients with haemophilia.
Page 1 of 18
2.
e Hympavzi
Do not use Hympavzi if you are allergic to marstacimab or any of the other ingredients of this medicine (listed in section 6). If you are not sure if you are allergic, talk to your doctor, pharmacist or nurse before using Hympavzi. Warnings and precautions Talk to your doctor before using Hympavzi. Before you start using Hympavzi, it is very important to talk to your doctor about using other factor VIII and factor IX products (products that help blood clot but work in a different way from Hympavzi) while using Hympavzi. You may need to use other factor VIII or factor IX products to treat episodes of breakthrough bleeding while using Hympavzi. Carefully follow your healthcare provider's instructions regarding when and how to use these factor VIII or factor IX products while using Hympavzi. Blood clots (thromboembolic events) Hympavzi increases how easily your blood clots and may cause blood clots in the blood vessels (so called thromboembolic events). Blood clots may be life-threatening. Tell your doctor if you have a history of blood clots or if you have a condition which increases your risk of blood clots. This includes if you: • • • • • • • • • • •
have a history of coronary artery disease (heart disease caused by narrowing or blockage of blood vessels supplying the heart muscle) have a history of ischaemic disease (reduced blood flow due to narrowed or blocked blood vessels) have a history of blood clots in veins or arteries have a genetic condition that increases your risk for blood clotting (such as Factor V Leiden) are bedridden, immobilised or off your feet for a long time are obese (overweight) are a smoker currently have serious infections currently have sepsis (blood poisoning) currently have trauma or crush injuries currently have cancer
Stop using Hympavzi, and talk to a doctor immediately if you notice any symptoms of a possible blood clot including the following side effects: • • • • • •
swelling or pain in arms or legs redness or discolouration in your arms or legs shortness of breath pain in chest or upper back fast heart rate coughing up blood
• • • • •
feeling faint headache numbness in your face eye pain or swelling trouble seeing
Allergic reactions Symptoms of allergic reaction have been seen in people using Hympavzi. Stop using Hympavzi and get medical help right away if you get any symptoms of a possible severe allergic reaction including the following: • •
rash, hives, generalised itching swelling of the face, lips, tongue or throat
• •
Page 2 of 18
difficulty breathing or swallowing dizziness
Children below the age of 12 years Hympavzi should not be used in children less than 1 year of age, and is not recommended for individuals below 12 years of age. The safety and benefits of this medicine are not yet known in this population. Other medicines and Hympavzi Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Pregnancy, contraception and breast-feeding If you are able to get pregnant, you should use an effective method of contraception (birth control) during treatment with Hympavzi and for at least 1 month after the last injection. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Your doctor will consider the benefit of you using Hympavzi against the risk to your unborn baby. If you are breast-feeding, ask your doctor for advice on whether to stop breast-feeding or stop using Hympavzi. Your doctor will consider the benefit of you using Hympavzi against the benefits for your nursing infant. Driving and using machines Hympavzi has no or limited effect on the ability to drive or use machines. Hympavzi contains polysorbate 80 This medicine contains 0.2 mg of polysorbate 80 in each mL. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies. Hympavzi contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 1 mL, that is to say essentially 'sodium-free'. 3.
How to use Hympavzi
Your treatment will be started under the supervision of a doctor qualified to care for patients with haemophilia. Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your healthcare provider will provide instructions for stopping your current treatment when switching from factor- or non-factor-based medicines to Hympavzi. Contact your healthcare provider if you are not sure what to do. If you are severely ill or need to undergo major surgery, tell your healthcare provider that you are using Hympavzi. Keeping a record Each time you use Hympavzi, record the name and batch number of the medicine.
you or your caregiver must carefully read and follow the detailed instructions for use on the reverse side of this leaflet. Where to inject Hympavzi
Like all medicines, this medicine can cause side effects, although not everybody gets them. Page 4 of 18
Serious side effects Hympavzi may cause a rash (seen in up to 1 in 100 people), which may be severe. Contact your doctor immediately if you have a severe rash; some rashes may be serious. Do not use Hympavzi again until you have talked with your doctor about your rash. Hympavzi may cause blood clots (thromboembolism) (seen in up to 1 in 100 people). Stop using Hympavzi and contact your doctor immediately if you notice any signs or symptoms of a possible blood clot. Please refer to section 2 "What you need to know before you use Hympavzi" for a list of possible symptoms of a blood clot (thromboembolic event). Other side effects Tell your doctor, nurse or pharmacist if you get any of these side effects. Very common (may affect more than 1 in 10 people)
How to store Hympavzi
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the pre-filled pen label and carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the pre-filled pen in the original carton in order to protect from light. Hympavzi may be removed from the refrigerator and stored in its original carton for up to 7 days at room temperature (up to 30 °C). Do not return Hympavzi to the refrigerator after storing at room temperature. If Hympavzi has been at room temperature for more than 7 days, throw it away, even if it contains unused medicine. Do not shake. Remove Hympavzi from the refrigerator prior to use. For a more comfortable injection, Hympavzi may be allowed to warm at room temperature in the carton for about 15 to 30 minutes away from direct sunlight prior to use. Before using the medicine, check the solution for particles or discolouration. Do not use if you notice that the medicine is cloudy, dark yellow, or contains flakes or particles.
Page 5 of 18
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
Hympavzi
Page 7 of 18
Page 8 of 18
Preparation Steps Step 1 – Getting Ready
Make sure the name Hympavzi appears on the carton and pen label. Check the pen for any visible damage such as cracks or leaks. Wash and dry your hands. Do not remove the cap until you are ready to inject. Throw away (dispose of) the pen if it is damaged, or if the pen or the carton containing the pen has been dropped.
Page 9 of 18
Step 2 – Check Date (EXP)
Page 10 of 18
Step 3 – Check Medicine
Page 11 of 18
Step 4 – Choose and Clean Injection Site
Page 12 of 18
Step 5 – Twist Off Cap
Page 13 of 18
Injection Steps Step 6 – Inject Medicine
Page 14 of 18
Step 7 – Remove Pen
Page 15 of 18
Step 8 – Check Window
Page 16 of 18
Step 9 – After Care
Page 17 of 18
Step 10 – Disposal
Page 18 of 18
What Hympavzi contains The active substance is marstacimab. The other ingredients are disodium edetate, L-histidine, L-histidine monohydrochloride, polysorbate 80 (E 433), sucrose, water for injections (see section 2 "Hympavzi contains polysorbate 80" and "Hympavzi contains sodium"). What Hympavzi looks like and contents of the pack Hympavzi is a clear and colourless to light yellow solution for injection (injection) in a pre-filled pen. Each pack of Hympavzi contains 1 pre-filled pen. Marketing Authorisation Holder Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom Manufacturer Pfizer Manufacturing Belgium NV Rijksweg 12 2870 Puurs-Sint-Amands Belgium This leaflet was last revised in 09/2025 For any information about this medicine, please contact: Medical Information, Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS. Telephone 01304 616161. Ref 2_0
Page 6 of 18
INSTRUCTIONS FOR USE Hympavzi® 150 mg solution for injection in pre-filled pen This 'Instructions for Use' contains information on how to inject Hympavzi. Read this 'Instructions for Use' carefully before using Hympavzi pre-filled pen and each time you get a refill prescription as there may be new information. Your doctor, nurse or pharmacist should show you or your caregiver how to prepare and inject a dose of Hympavzi the right way before you use it for the first time. Do not inject yourself or someone else until you have been shown how to inject Hympavzi. Important Information
Hympavzi 150 mg Solution for injection in pre-filled pen comes as injection containing 150mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Hympavzi 150 mg Solution for injection in pre-filled pen is marstacimab.
This leaflet reproduces the patient information leaflet approved for Hympavzi 150 mg Solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:
• severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or
• severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.
Treatment should be initiated under the supervision of a healthcare professional experienced in the treatment of haemophilia. Treatment should be initiated in a non-bleeding state.
Posology
The recommended dose for patients 12 years of age and older, weighing at least 35 kg, is an initial loading dose of 300 mg by subcutaneous injection followed thereafter by 150 mg by subcutaneous injection once weekly, at any time of day.
Duration of treatment
Hympavzi is intended for long-term prophylactic treatment.
Dose adjustments during treatment
A dose adjustment to 300 mg subcutaneous injection weekly can be considered in patients weighing ≥ 50 kg when control of bleeding events is judged to be inadequate by the healthcare professional. The maximum weekly dose of 300 mg should not be exceeded.
Guidance on treating breakthrough bleeds
Additional doses of Hympavzi should not be used to treat breakthrough bleeding events. For guidance on treatment in the event of breakthrough bleeds, see section 4.4.
Management in patients with acute severe illness
In acute severe illnesses with increased tissue factor expression, such as infection, sepsis, and crush injuries, potentiation of the inflammatory response via concomitant tissue factor pathway inhibitor (TFPI) inhibition could pose a risk of adverse reactions, especially thrombosis (see section 4.4).
Treatment of acute severe illness should be managed per local standard of care, and continued treatment with Hympavzi in this situation should be weighed against the potential risks involved. Additional monitoring for adverse reactions and the development of thromboembolism may be warranted in these patients when marstacimab is administered. Hympavzi should be temporarily interrupted if clinical symptoms, imaging, and/or laboratory findings consistent with thrombotic events occur, and managed as clinically indicated. Hympavzi therapy may be resumed once the patient has clinically recovered at the clinical judgement of the healthcare provider (see Missed dose section below).
Missed dose
If a dose is missed, administer as soon as possible before the day of the next scheduled dose, and then resume usual weekly dosing schedule.
If the missed dose is more than 13 days after the last dose, then a loading dose of 300 mg by subcutaneous injection should be administered followed thereafter by a resumption of 150 mg by subcutaneous injection once weekly.
Switching to Hympavzi
Switching from prophylactic factor replacement therapy to Hympavzi: Prior to initiation of Hympavzi, patients should discontinue treatment with clotting factor concentrates (factor VIII or factor IX concentrates). Patients can initiate Hympavzi at any time after discontinuing clotting factor concentrates.
Switching from non-factor-based haemophilia medicinal products to Hympavzi: No clinical study data are available to guide converting patients from non-factor-based medicinal products to marstacimab. Although a washout period has not been studied, one approach is to allow an adequate washout period (at least 5 half-lives) of the prior agent based on labelled half-life before initiating treatment with Hympavzi. Haemostatic support with clotting factor concentrates may be needed during the switch from other non-factor-based haemophilia medicinal products to Hympavzi.
Special populations
Hepatic impairment
No dose adjustments are recommended in patients with mild hepatic impairment (see section 5.2). Marstacimab has not been studied in patients with moderate or severe hepatic impairment.
Renal impairment
No dose adjustments are recommended in patients with mild renal impairment (see section 5.2). Marstacimab has not been studied in patients with moderate or severe renal impairment.
Elderly
No dose adjustments are recommended in patients over 65 years of age (see section 5.2).
Paediatric population
Hympavzi should not be used in children less than 1 year of age because of potential safety issues. The safety and efficacy of marstacimab in paediatric patients < 12 years of age have not yet been established. The safety and efficacy of marstacimab in adolescents with a body weight < 35 kg have not been established. No data are available.
Management in the perioperative setting
The safety and efficacy of marstacimab have not been formally evaluated in the surgical setting. Patients have had minor surgical procedures without discontinuing Hympavzi prophylaxis in clinical studies.
For major surgery, it is recommended to discontinue Hympavzi 6 to 12 days prior and initiate management per local standard of care with clotting factor concentrate and measures to manage the risk of venous thrombosis which can be elevated in the perioperative period. The product information for the clotting factor concentrate should be consulted for dose guidelines in patients with haemophilia undergoing major surgery. Resumption of Hympavzi therapy should take into account the overall clinical status of the patient, including the presence of post-surgical thromboembolic risk factors, use of other haemostatic products and other concomitant medicinal products (see Missed dose section above).
Method of administration
Hympavzi is for subcutaneous use only.
Hympavzi is intended for use under the guidance of a healthcare professional. After proper training in subcutaneous injection technique, a patient or caregiver may inject with the medicinal product if a healthcare professional determines that it is appropriate.
Prior to subcutaneous administration, Hympavzi may be removed from the refrigerator and allowed to warm at room temperature in the carton for about 15 to 30 minutes away from direct sunlight (see sections 6.4 and 6.6). The medicinal product should not be warmed by using a heat source such as hot water or a microwave.
The recommended injection sites are the abdomen (at least 5 cm away from the navel) and thigh. Other locations are acceptable if required. Administration of Hympavzi in the upper arm (pre-filled syringe only) and buttocks (pre‑filled pen only) should be performed by a caregiver or healthcare professional only. The medicinal product should not be administered into bony areas or areas where the skin is bruised, red, tender or hard, or areas where there are scars or stretch marks.
For the 300 mg loading dose, each of the two Hympavzi 150 mg injections should be administered at different injection sites.
It is recommended to rotate the injection site with each injection.
Hympavzi should not be injected into a vein or muscle.
During treatment with Hympavzi, other medicinal products for subcutaneous administration should, preferably, be injected at different anatomical sites.
For comprehensive instructions on the administration of the medicinal product, see section 6.6 and the 'Instructions for Use' provided at the end of the package leaflet.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Thromboembolic events
Removal of TFPI inhibition may increase a patient's coagulation potential and contribute to a patient's individual, multifactorial risk for thromboembolic events. Venous thrombotic events, including embolism, were reported in clinical studies with marstacimab (see section 4.8). These events occurred in individuals with multiple risk factors for thromboembolism. The following patients may be at an increased risk of thromboembolic events with use of this medicinal product:
• patients with a history of coronary artery disease, venous or arterial thrombosis or ischaemic disease,
• patients with known risk factors for thromboembolism, including but not limited to genetic prothrombotic conditions (e.g. Factor V Leiden), patients with prolonged periods of immobilisation, obesity, and smoking,
• patients currently experiencing an acute severe illness with increased tissue factor expression (such as serious infection, sepsis, trauma, crush injuries, cancer).
Marstacimab has not been studied in patients with a history of previous thromboembolic events (see section 5.1) and there is limited experience in patients with acute severe illness.
The use of other anti-tissue factor pathway inhibitor (anti-TFPI) products has been associated with the development of thromboembolic complications in patients exposed to additional haemostatic agents (i.e. bypassing agents) in close proximity. Factor VIII and factor IX products have been safely administered for the treatment of breakthrough bleeds in patients receiving marstacimab. If factor VIII or factor IX products are indicated in a patient receiving Hympavzi prophylaxis, the minimum effective dose of factor VIII or factor IX product according to the product label is recommended.
The benefit and risk of using Hympavzi in patients with a history of thromboembolic events, with known risk factors for thromboembolism, or currently experiencing an acute severe illness should be considered. Patients at risk should be monitored for early signs of thrombosis, and prophylaxis measures against thromboembolism should be instituted according to current recommendations and standard of care. Hympavzi prophylaxis should be interrupted if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated.
Guidance on treating breakthrough bleeds
Factor VIII and factor IX products can be administered for the treatment of breakthrough bleeds in patients receiving Hympavzi. Additional doses of Hympavzi should not be used to treat breakthrough bleeding events. Healthcare professionals should discuss with all patients and/or caregivers about the dose and schedule of clotting factor concentrates to use, if required, while receiving Hympavzi prophylaxis, including using the lowest possible effective dose of clotting factor concentrate. Healthcare professionals should refer to the product information for the clotting factor concentrate being used.
Hypersensitivity reactions
Cutaneous reactions of rash and pruritus that may reflect drug hypersensitivity have occurred in marstacimab-treated patients (see section 4.8). If Hympavzi-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue Hympavzi and seek immediate emergency treatment.
Patient with factor inhibitor
In an ongoing clinical study outside the approved indication, in haemophilia patients with inhibitors treated with marstacimab, one (2.9%) patient with severe haemophilia B and a history of allergic reaction to exogenous factor IX experienced severe rash with onset at approximately 9 months. The patient required a prolonged course of oral corticosteroids for resolution, and treatment with marstacimab was discontinued.
Effects of marstacimab on coagulation tests
Marstacimab therapy does not produce clinically meaningful changes in standard measures of coagulation including activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT).
Excipients
Polysorbate content
This medicinal product contains polysorbate 80. Polysorbate 80 may cause hypersensitivity reactions.
Sodium content
This medicinal product contains less than 1 mmol sodium (23 mg) per 1 mL, that is to say essentially 'sodium-free'.
No clinical drug interaction studies with marstacimab have been conducted.
As a monoclonal antibody (mAb), marstacimab is expected to be cleared through catabolic pathways. Thus an impact on its clearance via an interaction with concomitant medicinal products cleared via non-catabolic pathways is unlikely. Indirect effect of a biologic such as marstacimab on the expression of cytochrome P450 enzymes is also not expected.
Women of childbearing potential
Women of childbearing potential receiving Hympavzi should use effective contraception during, and for at least 1 month after cessation of Hympavzi treatment.
Pregnancy
There are no clinical studies of marstacimab use in pregnant women. Animal reproduction studies have not been conducted with marstacimab. It is not known whether Hympavzi can cause foetal harm when administered to a pregnant woman or can affect reproduction capacity. Hympavzi should be used during pregnancy only if the potential benefit for the mother outweighs the risk to the foetus taking into account that, during pregnancy and after parturition, the risk for thrombosis is increased and that several pregnancy complications are linked to an increased risk for disseminated intravascular coagulation (DIC).
Breast-feeding
It is not known whether marstacimab is excreted in human milk. No studies have been conducted to assess the impact of marstacimab on milk production or its presence in breast milk. Human IgG is known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast‑fed infant cannot be excluded during this short period. Afterwards, marstacimab could be used during breast‑feeding if clinically needed.
Fertility
Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3). No fertility data are available in humans. Thus, the effect of marstacimab on male and female fertility is unknown.
Hympavzi has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
The overall safety profile of marstacimab is based on data from clinical studies. The most serious adverse drug reaction reported from the clinical studies with marstacimab was thrombosis (0.9%) (see section 4.4).
The most frequently reported adverse reactions after treatment with marstacimab were injection site reactions (ISRs) (11.2%).
Tabulated list of adverse reactions
Safety data in Table 1 are based on pooled data from the Phase 3 safety and efficacy study (BASIS) and its open-label extension (OLE) study (see section 5.1). The data from the pivotal Phase 3 study 12‑month Active Treatment Phase reflects exposure of 116 male patients with haemophilia A or B without inhibitors to marstacimab administered once weekly. Ninety-seven (83.6%) patients were adults (18 years of age and older) and 19 (16.4%) were adolescents (12 years up to < 18 years). At the time of data cut-off, a total of 87 of the 116 patients completing the 12-month treatment period subsequently enrolled in the OLE study. The median duration of exposure was 518.5 days (range 28 to 847 days).
Table 1 summarises the adverse reactions reported in patients who received marstacimab prophylaxis. The adverse reactions listed in the table below are presented by system organ class (SOC) and frequency categories, defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000) or frequency not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Table 1. Adverse reactions
System organ class
Adverse reaction
Frequency
Nervous system disorders
Headache
Common
Vascular disorders
Hypertension
Thromboembolic events (thrombosis,b)
Common
Uncommon
Skin and subcutaneous tissue disorders
Pruritus
Rasha
Common
Uncommon
General disorders and administrations site conditions
Injection site reactionsa
Very common
a. see 'Description of selected adverse reactions'
b. ADR reported in the open-label extension study post-data cut‑off.
Description of selected adverse reactions
Injection site reactions
In total, 11.2% of patients treated with marstacimab reported ISRs. The majority of ISRs observed in marstacimab clinical studies were transient and reported as mild to moderate in severity. No occurrences of injection site reaction led to a dose adjustment or drug discontinuation. ISRs include injection site bruising, injection site erythema, injection site haematoma, injection site induration, injection site oedema, injection site pain, injection site pruritus, and injection site swelling.
Rash
In the non-inhibitor population, 0.9% of patients reported non-serious rash (Grade 1).
Paediatric population
The paediatric population studied comprises a total of 19 adolescent patients (from 12 to < 18 years of age). The safety profile of marstacimab was overall consistent between adolescents and adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There is limited experience with overdose of marstacimab.
No serious adverse events occurred in a small number of adult patients weighing ≥ 50 kg who had up to 3 months of exposure to marstacimab at 450 mg administered subcutaneously weekly during early phase studies. However, this was a small group, and the effect of longer-term high exposures is unknown. Receiving higher doses than recommended may result in hypercoagulability.
Patients who receive an accidental overdose should immediately contact their healthcare provider and be monitored closely. In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and/or hypercoagulability and appropriate symptomatic treatment be instituted immediately.
Paediatric population
Doses in excess of 150 mg per week for adolescents aged 12 to 17 years weighing < 50 kg have not been studied. No case of overdose has been reported in the paediatric population. The principles described above apply to the management of overdose in the paediatric population.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Hympavzi 150 mg Solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.